- Home
- IKT vs MCRB Comparison
IKT vs MCRB Comparison
Compare IKT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- MCRB
- Stock Information
- Founded
- IKT 2008
- MCRB 2010
- Country
- IKT United States
- MCRB United States
- Employees
- IKT N/A
- MCRB N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- IKT Health Care
- MCRB Health Care
- Exchange
- IKT Nasdaq
- MCRB Nasdaq
- Market Cap
- IKT 140.5M
- MCRB 165.3M
- IPO Year
- IKT 2020
- MCRB 2015
- Fundamental
- Price
- IKT $1.56
- MCRB $17.61
- Analyst Decision
- IKT Buy
- MCRB Hold
- Analyst Count
- IKT 2
- MCRB 4
- Target Price
- IKT $8.00
- MCRB $73.67
- AVG Volume (30 Days)
- IKT 92.1K
- MCRB 247.1K
- Earning Date
- IKT 11-13-2025
- MCRB 11-12-2025
- Dividend Yield
- IKT N/A
- MCRB N/A
- EPS Growth
- IKT N/A
- MCRB N/A
- EPS
- IKT N/A
- MCRB 10.22
- Revenue
- IKT N/A
- MCRB N/A
- Revenue This Year
- IKT N/A
- MCRB N/A
- Revenue Next Year
- IKT N/A
- MCRB N/A
- P/E Ratio
- IKT N/A
- MCRB $1.71
- Revenue Growth
- IKT N/A
- MCRB N/A
- 52 Week Low
- IKT $1.12
- MCRB $6.53
- 52 Week High
- IKT $4.20
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- IKT 42.51
- MCRB 50.98
- Support Level
- IKT $1.50
- MCRB $14.22
- Resistance Level
- IKT $1.73
- MCRB $24.67
- Average True Range (ATR)
- IKT 0.09
- MCRB 2.01
- MACD
- IKT -0.02
- MCRB -0.47
- Stochastic Oscillator
- IKT 17.34
- MCRB 32.46
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.